All In Biotech

Drug Trial Radar · NCT04820309

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia

Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

566

Actual

Start

Jun 2, 2021

Primary completion

May 24, 2024

Study completion May 24, 2024

Sponsor

Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Mar 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in de novo subjects with Diagnostic and Statistical Manual-Fifth Edition (DSM-5) schizophrenia. In this OL study, all subjects will receive KarXT (a fixed combination of xanomeline 125 mg and trospium chloride 30 mg twice daily \[BID\]) for up to 52 weeks. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with a DSM-5 diagnosis of schizophrenia. The secondary objective of this study is to assess the long-term efficacy and characterize the pharmacokinetics of xanomeline and trospium after administration of KarXT.

Conditions

  • Schizophrenia

Interventions

  • Xanomeline and Trospium Chloride CapsulesDrug

    Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From time of consent to end of study (approximately 400 days)

Locations

117 sites in 2 countries. Site status is shown where the registry gives one.

  • Local Institution - 011-238

    Little Rock, Arkansas

  • Woodland International Research Group

    Little Rock, Arkansas

  • Local Institution - 011-201

    Rogers, Arkansas

  • Woodland Research Northwest

    Rogers, Arkansas

  • Local Institution - 011-240

    Anaheim, California

  • Advanced Research Center, Inc.

    Anaheim, California

  • Clinical Innovations, Inc

    Bellflower, California

  • Local Institution - 011-222

    Bellflower, California

  • Local Institution - 011-263

    Bellflower, California

  • Local Institution - 011-257

    Cerritos, California

  • ATP Clinical Research Inc

    Costa Mesa, California

  • ATP Clinical Research, Inc.

    Costa Mesa, California

  • Local Institution - 011-206

    Culver City, California

  • ProScience Research Group

    Culver City, California

  • Local Institution - 011-253

    Garden Grove, California

  • Local Institution - 011-202

    Glendale, California

  • Behavioral Clinical Research, Inc.

    Glendale, California

  • Omega Clinical Trials

    La Habra, California

  • Omega Clinical Trials

    La Habra, California

  • Alliance for Wellness dba Alliance for Research

    Long Beach, California

  • Alliance for Wellness

    Long Beach, California

  • North County Clinical Research (NCCR)

    Oceanside, California

  • Excell Research Inc

    Oceanside, California

  • Local Institution - 011-229

    Oceanside, California

  • Local Institution - 011-242

    Orange, California

  • NRC Research Institute

    Orange, California

  • CNRI-Los Angeles, LLC

    Pico Rivera, California

  • Local Institution - 011-244

    Pico Rivera, California

  • CITrials

    Riverside, California

  • Local Institution - 011-233

    Riverside, California

  • CITrials

    Santa Ana, California

  • Local Institution - 011-251

    Santa Rosa, California

  • Siyan Clinical Research

    Santa Rosa, California

  • Local Institution - 011-246

    Sherman Oaks, California

  • Schuster Medical Research Institute

    Sherman Oaks, California

  • Collaborative Neuroscience Research

    Torrance, California

  • Local Institution - 011-252

    Torrance, California

  • Local Institution - 011-224

    Hallandale, Florida

  • Velocity Clinical Research, Hallandale Beach

    Hallandale, Florida

  • Local Institution - 011-261

    Hollywood, Florida

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.